Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2026-07-02 16:05:31 ET · period of report 2026-06-30 · accession 0001918845-26-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-02 16:05 | 2026-06-30 | AVTX | Doyle Mittie | Chief Medical Off | M - OptEx | $10.89 | +4,654 | 56.4K | +9% | +$50.7K |
| DT | 2026-07-02 16:05 | 2026-06-30 | AVTX | Doyle Mittie | Chief Medical Off | S - Sale+OE | $20.00 | -4,654 | 51.8K | -8% | -$93.1K |
| DMT | 2026-07-02 16:05 | 2026-06-30 | AVTX | Doyle Mittie | Chief Medical Off | M - OptEx | $0.00 | -4,654 | 115.1K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | M | A | 2,875 | $12.65 | 54,651 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
| 2 | Common | Common Stock | 2026-06-30 | M | A | 1,779 | $8.04 | 56,430 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
| 3 | Common | Common Stock | 2026-06-30 | S | D | 4,654 | $20.00 | 51,776 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 2,875 | $0.00 | 125,750 | D | $12.65 · — to 2034-07-15 | 2,875 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 1,779 | $0.00 | 115,092 | D | $8.04 · — to 2035-01-28 | 1,779 Common Stock | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F3) The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date. |